SciClone Pharmaceuticals, Inc.  

(Public, NASDAQ:SCLN)   Watch this stock  
Find more results for SciClone Pharmaceuticals, Inc
7.90
0.00 (0.00%)
Oct 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.77 - 7.99
52 week 4.24 - 8.00
Open 7.87
Vol / Avg. 420,782.00/566,269.00
Mkt cap 403.53M
P/E 18.76
Div/yield     -
EPS 0.42
Shares 51.08M
Beta 2.13
Inst. own 60%
Nov 4, 2014
Q3 2014 SciClone Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 26, 2014
SciClone Pharmaceuticals Inc at BioCentury Publications NewsMakers in the Biotech Industry
Sep 11, 2014
SciClone Pharmaceuticals Inc at Aegis Capital Corp Healthcare & Technology Conference
Aug 11, 2014
Q2 2014 SciClone Pharmaceuticals Inc Earnings Call - Webcast
Aug 11, 2014
Q2 2014 SciClone Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 29.65% 8.63%
Operating margin 29.65% 8.21%
EBITD margin - 12.29%
Return on average assets 22.12% 6.20%
Return on average equity 25.56% 7.57%
Employees 570 -
CDP Score - -

Address

Suite 900, 950 Tower Lane
FOSTER CITY, CA 94404-2125
United States - Map
+1-650-3583456 (Phone)
+1-650-3583469 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

SciClone Pharmaceuticals, Inc. (SciClone) is a specialty pharmaceutical company. The Company has a product portfolio of therapies for oncology, infectious diseases, cardiovascular, urological, respiratory and central nervous system disorders. The Company�s main product is ZADAXIN (thymalfasin), which is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers. In China, thymalfasin is also included in the treatment guidelines issued by the Ministry of Health for liver cancer. SciClone�s marketed portfolio also includes Depakine, the prescribed broad-spectrum anti-convulsant in China; Tritace, an ACE inhibitor for the treatment of hypertension; Stilnox, a hypnotic for the short-term treatment of insomnia (marketed as Ambien in the United States), and Aggrastat, an intervention cardiology product. On April 18, 2011, the Company acquired NovaMed Pharmaceuticals, Inc.

Officers and directors

Jon S. Saxe Independent Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Friedhelm Blobel Ph.D. President, Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Wilson W. Cheung Chief Financial Officer, Senior Vice President - Finance, Secretary
Age: 45
Bio & Compensation  - Reuters
Hong Zhao Chief Executive Officer - China Operations
Age: 50
Bio & Compensation  - Reuters
Raymond A. Low CPA Vice President - Finance, Controller
Age: 56
Bio & Compensation  - Reuters
Charles Meng Vice President - Compliance, General Counsel
Age: 51
Bio & Compensation  - Reuters
Min Yin CPA Vice President - Internal Audit
Age: 42
Bio & Compensation  - Reuters
Lan Xie CPA Vice President Finance, China Chief Financial Officer
Age: 41
Bio & Compensation  - Reuters
Nancy T. Chang Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Richard J. Hawkins Independent Director
Age: 65
Bio & Compensation  - Reuters